Advocacy intelligence hub — real-time data for patient organizations
MavriX Bio, LLC — PHASE1, PHASE2
Ultragenyx Pharmaceutical Inc — PHASE2
Assistance Publique - Hôpitaux de Paris
Ultragenyx Pharmaceutical Inc — PHASE3
Ultragenyx Pharmaceutical Inc — PHASE3
Puerta de Hierro University Hospital
IRCCS Eugenio Medea
Ionis Pharmaceuticals, Inc. — PHASE1, PHASE2
Centre Hospitalier Universitaire de Liege
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
View all Angelman syndrome due to a point mutation specialists →